RxDoctor Payments Data

Childebert St Louis, MD

Family Medicine · New City, NYNPI 1780845834

Payments from drug & device makers

$1,417in general payments, 2019–2025

Across 41 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$418
  • Johnson & Johnson$183
  • Novartis$169
  • AbbVie$146
  • AstraZeneca$142
  • Braeburn Inc.$72
  • plus $286 from 8 others

What the payments were for

  • Food & beverage$1,417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,417 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$200,321
Medicare patients
770
Services billed
2,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$139,361
JanuviaSitagliptin Phosphate69$47,875
OzempicSemaglutide43$39,882
JardianceEmpagliflozin57$39,638
FarxigaDapagliflozin Propanediol54$37,715
XareltoRivaroxaban77$33,800
EntrestoSacubitril/Valsartan50$32,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$22,431
JanumetSitagliptin Phos/Metformin Hcl16$20,963
RexultiBrexpiprazole20$20,658
Janumet XrSitagliptin Phos/Metformin Hcl14$16,014
Atrovent HfaIpratropium Bromide24$12,253
XifaxanRifaximin12$11,992
LinzessLinaclotide19$11,742
LokelmaSodium Zirconium Cyclosilicate24$10,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$20$149,146311 claims
AstraZenecaFarxiga, Lokelma, Brilinta$142$52,06396 claims
Novo NordiskOzempic$63$39,88243 claims
Johnson & JohnsonXarelto$183$33,80077 claims
NovartisEntresto$169$32,17250 claims
Otsuka America Pharmaceutical, Inc.Rexulti$418$20,65820 claims
AbbVieLinzess, Lumigan$146$15,59534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in New City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →